Justin Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Justin Lee has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Mikhail G. Shapiro
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, USA
7 shared publications - Bill Ling
Division of Chemistry and Chemical Engineering, California Institute of Technology
3 shared publications - Bilge Gungoren
Division of Chemistry and Chemical Engineering California Institute of Technology Pasadena CA 91125 USA
2 shared publications - Cameron A. B. Smith
Division of Chemistry and Chemical Engineering, California Institute of Technology; Pasadena, CA 91125, USA
2 shared publications - Dan Ilya Piraner
Department of Microbiology and Immunology, University of California San Francisco, San Francisco, California
2 shared publications - Edward Wolfgang Lee
Division of Interventional Radiology, Department of Radiology, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA; Division of Liver and Pancreas Transplant Surgery, Department of Surgery, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA
2 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (11) , 5456-5459
From embolization to access: Wire-enabled crossing of a coil pack for targeted distal re-treatment
- 19 August 2026
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (11) , 5456-5459
Open AccessFrom embolization to access: Wire-enabled crossing of a coil pack for targeted distal re-treatment
- 1 July 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (1) , e253870
Robotic-assisted 90Y Transarterial Radioembolization for Treatment of Hepatocellular Carcinoma: Initial Experience.
Robotic-assisted yttrium 90 transarterial radioembolization enables hepatic radioembolization while potentially eliminating operator radiation exposure and achieving comparable technical success, highlighting its feasibility and potential to enhance safety in interventional radiology.
- 1 July 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (1) , e253870
Robotic-assisted 90Y Transarterial Radioembolization for Treatment of Hepatocellular Carcinoma: Initial Experience.
Robotic-assisted yttrium 90 transarterial radioembolization enables hepatic radioembolization while potentially eliminating operator radiation exposure and achieving comparable technical success, highlighting its feasibility and potential to enhance safety in interventional radiology.
- 1 September 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 7 (5) , e250340
They Not Like US: Imaging Tumor Immune Resistance with Contrast-enhanced US
- 1 September 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 7 (5) , e250340
They Not Like US: Imaging Tumor Immune Resistance with Contrast-enhanced US
- Open Access
- 15 March 2024
- Published by Wiley in Advanced Materials
- Vol. 36 (28) , e2307106
Truly Tiny Acoustic Biomolecules for Ultrasound Imaging and Therapy
Nanotechnology offers significant advantages for medical imaging and therapy, including enhanced contrast and precision targeting. However, integrating these benefits into ultrasonography is challenging due to the size and stability constraints of conventional bubble‐based agents. Here bicones, truly tiny acoustic contrast agents based on gas vesicles (GVs), a unique class of air‐filled protein nanostructures naturally produced in buoyant microbes, are described. It is shown that these sub‐80 nm particles can be effectively detected both in vitro and in vivo, infiltrate tumors via leaky vasculature, deliver potent mechanical effects through ultrasound‐induced inertial cavitation, and are easily engineered for molecular targeting, prolonged circulation time, and payload conjugation.
- 15 March 2024
- Published by Wiley in Advanced Materials
- Vol. 36 (28) , e2307106
Open AccessTruly Tiny Acoustic Biomolecules for Ultrasound Imaging and Therapy
Nanotechnology offers significant advantages for medical imaging and therapy, including enhanced contrast and precision targeting. However, integrating these benefits into ultrasonography is challenging due to the size and stability constraints of conventional bubble‐based agents. Here bicones, truly tiny acoustic contrast agents based on gas vesicles (GVs), a unique class of air‐filled protein nanostructures naturally produced in buoyant microbes, are described. It is shown that these sub‐80 nm particles can be effectively detected both in vitro and in vivo, infiltrate tumors via leaky vasculature, deliver potent mechanical effects through ultrasound‐induced inertial cavitation, and are easily engineered for molecular targeting, prolonged circulation time, and payload conjugation.
- Open Access
Truly tiny acoustic biomolecules for ultrasound imaging and therapy
Nanotechnology offers significant advantages for medical imaging and therapy, including enhanced contrast and precision targeting. However, integrating these benefits into ultrasonography has been challenging due to the size and stability constraints of conventional bubble-based agents. Here we describe bicones, truly tiny acoustic contrast agents based on gas vesicles, a unique class of air-filled protein nanostructures naturally produced in buoyant microbes. We show that these sub-80 nm particles can be effectively detected both in vitro and in vivo, infiltrate tumors via leaky vasculature, deliver potent mechanical effects through ultrasound-induced inertial cavitation, and are easily engineered for molecular targeting, prolonged circulation time, and payload conjugation.
Open AccessTruly tiny acoustic biomolecules for ultrasound imaging and therapy
Nanotechnology offers significant advantages for medical imaging and therapy, including enhanced contrast and precision targeting. However, integrating these benefits into ultrasonography has been challenging due to the size and stability constraints of conventional bubble-based agents. Here we describe bicones, truly tiny acoustic contrast agents based on gas vesicles, a unique class of air-filled protein nanostructures naturally produced in buoyant microbes. We show that these sub-80 nm particles can be effectively detected both in vitro and in vivo, infiltrate tumors via leaky vasculature, deliver potent mechanical effects through ultrasound-induced inertial cavitation, and are easily engineered for molecular targeting, prolonged circulation time, and payload conjugation.
- 24 February 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (8) , eadd9186
Biomolecular actuators for genetically selective acoustic manipulation of cells
The ability to physically manipulate specific cells is critical for the fields of biomedicine, synthetic biology, and living materials. Ultrasound has the ability to manipulate cells with high spatiotemporal precision via acoustic radiation force (ARF). However, because most cells have similar acoustic properties, this capability is disconnected from cellular genetic programs. Here, we show that gas vesicles (GVs)—a unique class of gas-filled protein nanostructures—can serve as genetically encodable actuators for selective acoustic manipulation. Because of their lower density and higher compressibility relative to water, GVs experience strong ARF with opposite polarity to most other materials. When expressed inside cells, GVs invert the cells’ acoustic contrast and amplify the magnitude of their ARF, allowing the cells to be selectively manipulated with sound waves based on their genotype. GVs provide a direct link between gene expression and acoustomechanical actuation, opening a paradigm for selective cellular control in a broad range of contexts.
- 24 February 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (8) , eadd9186
Biomolecular actuators for genetically selective acoustic manipulation of cells
The ability to physically manipulate specific cells is critical for the fields of biomedicine, synthetic biology, and living materials. Ultrasound has the ability to manipulate cells with high spatiotemporal precision via acoustic radiation force (ARF). However, because most cells have similar acoustic properties, this capability is disconnected from cellular genetic programs. Here, we show that gas vesicles (GVs)—a unique class of gas-filled protein nanostructures—can serve as genetically encodable actuators for selective acoustic manipulation. Because of their lower density and higher compressibility relative to water, GVs experience strong ARF with opposite polarity to most other materials. When expressed inside cells, GVs invert the cells’ acoustic contrast and amplify the magnitude of their ARF, allowing the cells to be selectively manipulated with sound waves based on their genotype. GVs provide a direct link between gene expression and acoustomechanical actuation, opening a paradigm for selective cellular control in a broad range of contexts.
- 29 October 2020
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 20 (11) , 8127-8134
Genetically Encoded Phase Contrast Agents for Digital Holographic Microscopy
Quantitative phase imaging and digital holographic microscopy have shown great promise for visualizing the motion, structure, and physiology of microorganisms and mammalian cells in three dimensions. However, these imaging techniques currently lack molecular contrast agents analogous to the fluorescent dyes and proteins that have revolutionized fluorescence microscopy. Here we introduce the first genetically encodable phase contrast agents based on gas vesicles. The relatively low index of refraction of the air-filled core of gas vesicles results in optical phase advancement relative to aqueous media, making them a “positive” phase contrast agent easily distinguished from organelles, dyes, or microminerals. We demonstrate this capability by identifying and tracking the motion of gas vesicles and gas vesicle-expressing bacteria using digital holographic microscopy, and by imaging the uptake of engineered gas vesicles by mammalian cells. These results give phase imaging a biomolecular contrast agent, expanding the capabilities of this powerful technology for three-dimensional biological imaging.
- 29 October 2020
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 20 (11) , 8127-8134
Genetically Encoded Phase Contrast Agents for Digital Holographic Microscopy
Quantitative phase imaging and digital holographic microscopy have shown great promise for visualizing the motion, structure, and physiology of microorganisms and mammalian cells in three dimensions. However, these imaging techniques currently lack molecular contrast agents analogous to the fluorescent dyes and proteins that have revolutionized fluorescence microscopy. Here we introduce the first genetically encodable phase contrast agents based on gas vesicles. The relatively low index of refraction of the air-filled core of gas vesicles results in optical phase advancement relative to aqueous media, making them a “positive” phase contrast agent easily distinguished from organelles, dyes, or microminerals. We demonstrate this capability by identifying and tracking the motion of gas vesicles and gas vesicle-expressing bacteria using digital holographic microscopy, and by imaging the uptake of engineered gas vesicles by mammalian cells. These results give phase imaging a biomolecular contrast agent, expanding the capabilities of this powerful technology for three-dimensional biological imaging.
- 14 September 2020
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 14 (9) , 12210-12221
Biomolecular Ultrasound Imaging of Phagolysosomal Function
Phagocytic clearance and lysosomal processing of pathogens and debris are essential functions of the innate immune system. However, the assessment of these functions in vivo is challenging because most nanoscale contrast agents compatible with non-invasive imaging techniques are made from non-biodegradable synthetic materials that do not undergo regular lysosomal degradation. To overcome this challenge, we describe the use of an all-protein contrast agent to directly visualize and quantify phagocytic and lysosomal activities in vivo by ultrasound imaging. This contrast agent is based on gas vesicles (GVs), a class of air-filled protein nanostructures naturally expressed by buoyant microbes. Using a combination of ultrasound imaging, pharmacology, immunohistology and live-cell optical microscopy, we show that after intravenous injection, GVs are cleared from circulation by liver-resident macrophages. Once internalized, the GVs undergo lysosomal degradation, resulting in the elimination of their ultrasound contrast. By non-invasively monitoring the temporal dynamics of GV-generated ultrasound signal in circulation and in the liver and fitting them with a pharmacokinetic model, we can quantify the rates of phagocytosis and lysosomal degradation in living animals. We demonstrate the utility of this method by showing how these rates are perturbed in two models of liver dysfunction: phagocyte deficiency and non-alcoholic fatty liver disease. The combination of proteolytically-degradable nanoscale contrast agents and quantitative ultrasound imaging thus enables non-invasive functional imaging of cellular degradative processes.
- 14 September 2020
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 14 (9) , 12210-12221
Biomolecular Ultrasound Imaging of Phagolysosomal Function
Phagocytic clearance and lysosomal processing of pathogens and debris are essential functions of the innate immune system. However, the assessment of these functions in vivo is challenging because most nanoscale contrast agents compatible with non-invasive imaging techniques are made from non-biodegradable synthetic materials that do not undergo regular lysosomal degradation. To overcome this challenge, we describe the use of an all-protein contrast agent to directly visualize and quantify phagocytic and lysosomal activities in vivo by ultrasound imaging. This contrast agent is based on gas vesicles (GVs), a class of air-filled protein nanostructures naturally expressed by buoyant microbes. Using a combination of ultrasound imaging, pharmacology, immunohistology and live-cell optical microscopy, we show that after intravenous injection, GVs are cleared from circulation by liver-resident macrophages. Once internalized, the GVs undergo lysosomal degradation, resulting in the elimination of their ultrasound contrast. By non-invasively monitoring the temporal dynamics of GV-generated ultrasound signal in circulation and in the liver and fitting them with a pharmacokinetic model, we can quantify the rates of phagocytosis and lysosomal degradation in living animals. We demonstrate the utility of this method by showing how these rates are perturbed in two models of liver dysfunction: phagocyte deficiency and non-alcoholic fatty liver disease. The combination of proteolytically-degradable nanoscale contrast agents and quantitative ultrasound imaging thus enables non-invasive functional imaging of cellular degradative processes.
- 30 July 2020
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 9 (8) , 1941-1950
Thermal Control of Engineered T-cells
Genetically engineered T-cells are being developed to perform a variety of therapeutic functions. However, no robust mechanisms exist to externally control the activity of T-cells at specific locations within the body. Such spatiotemporal control could help mitigate potential off-target toxicity due to incomplete molecular specificity in applications such as T-cell immunotherapy against solid tumors. Temperature is a versatile external control signal that can be delivered to target tissues in vivo using techniques such as focused ultrasound and magnetic hyperthermia. Here, we test the ability of heat shock promoters to mediate thermal actuation of genetic circuits in primary human T-cells in the well-tolerated temperature range of 37–42ºC, and introduce genetic architectures enabling the tuning of the amplitude and duration of thermal activation. We demonstrate the use of these circuits to control the expression of chimeric antigen receptors and cytokines, and the killing of target tumor cells. This technology provides a critical tool to direct the activity of T-cells after they are deployed inside the body.
- 30 July 2020
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 9 (8) , 1941-1950
Thermal Control of Engineered T-cells
Genetically engineered T-cells are being developed to perform a variety of therapeutic functions. However, no robust mechanisms exist to externally control the activity of T-cells at specific locations within the body. Such spatiotemporal control could help mitigate potential off-target toxicity due to incomplete molecular specificity in applications such as T-cell immunotherapy against solid tumors. Temperature is a versatile external control signal that can be delivered to target tissues in vivo using techniques such as focused ultrasound and magnetic hyperthermia. Here, we test the ability of heat shock promoters to mediate thermal actuation of genetic circuits in primary human T-cells in the well-tolerated temperature range of 37–42ºC, and introduce genetic architectures enabling the tuning of the amplitude and duration of thermal activation. We demonstrate the use of these circuits to control the expression of chimeric antigen receptors and cytokines, and the killing of target tumor cells. This technology provides a critical tool to direct the activity of T-cells after they are deployed inside the body.
- Open Access
Thermal Control of T-cell Immunotherapy
Genetically engineered T-cells are being developed to perform a variety of therapeutic functions. However, no robust mechanisms exist to externally control the activity of T-cells at specific locations within the body. Such spatiotemporal control could help mitigate potential off-target toxicity due to incomplete molecular specificity in applications such as T-cell immunotherapy against solid tumors. Temperature is a versatile external control signal that can be delivered to target tissues in vivo using techniques such as focused ultrasound and magnetic hyperthermia. Here, we test the ability of heat shock promoters to mediate thermal actuation of genetic circuits in primary human T-cells in the well-tolerated temperature range of 37–42°C, and introduce genetic architectures enabling the tuning of the amplitude and duration of thermal activation. We demonstrate the use of these circuits to control the expression of chimeric antigen receptors and cytokines, and the killing of target tumor cells. This technology provides a critical tool to direct the activity of T-cells after they are deployed inside the body.
Open AccessThermal Control of T-cell Immunotherapy
Genetically engineered T-cells are being developed to perform a variety of therapeutic functions. However, no robust mechanisms exist to externally control the activity of T-cells at specific locations within the body. Such spatiotemporal control could help mitigate potential off-target toxicity due to incomplete molecular specificity in applications such as T-cell immunotherapy against solid tumors. Temperature is a versatile external control signal that can be delivered to target tissues in vivo using techniques such as focused ultrasound and magnetic hyperthermia. Here, we test the ability of heat shock promoters to mediate thermal actuation of genetic circuits in primary human T-cells in the well-tolerated temperature range of 37–42°C, and introduce genetic architectures enabling the tuning of the amplitude and duration of thermal activation. We demonstrate the use of these circuits to control the expression of chimeric antigen receptors and cytokines, and the killing of target tumor cells. This technology provides a critical tool to direct the activity of T-cells after they are deployed inside the body.